Welcome to our dedicated page for abrdn Healthcare Opportunities news (Ticker: THQ), a resource for investors and traders seeking the latest updates and insights on abrdn Healthcare Opportunities stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect abrdn Healthcare Opportunities's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of abrdn Healthcare Opportunities's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 10, 2023, the Tekla Healthcare Opportunities Fund (NYSE: THQ) announced a monthly cash distribution of $0.1125 per share. The record date for this distribution is set for April 20, 2023, with a payable date of April 28, 2023. The Fund will trade ex-distribution on April 19, 2023. Only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan will have their cash distributions automatically reinvested in shares. Tekla Healthcare Opportunities Fund focuses on investments in the healthcare sector, guided by Tekla Capital Management LLC based in Boston. Shares can be purchased through any securities broker on the New York Stock Exchange.
Tekla Healthcare Opportunities Fund (NYSE: THQ) announced the renewal of its share repurchase program, enabling the purchase of up to 12% of its outstanding common shares until July 14, 2024. This decision follows the Board's review aimed at enhancing shareholder value and reducing the market price discount relative to the net asset value (NAV) per share. The program is expected to increase the Fund's NAV per share and improve share liquidity. However, there are no guarantees regarding the timing or amount of share repurchases, nor assurances that the market price will increase as a result.
On March 10, 2023, the Tekla Healthcare Opportunities Fund (NYSE: THQ) announced a monthly cash distribution of $0.1125 per share. The record date is set for March 20, 2023, with payments scheduled on March 31, 2023. The ex-distribution date is March 17, 2023. Notably, only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan (DRIP) will automatically reinvest cash distributions in shares.
Managed by Tekla Capital Management LLC based in Boston, THQ focuses on investments within the healthcare sector. Investors can purchase shares of the Fund through the New York Stock Exchange.
On February 10, 2023, Tekla Healthcare Opportunities Fund (NYSE:THQ) announced a monthly cash distribution of $0.1125 per share. The record date for this distribution is February 21, 2023, with a payable date of February 28, 2023. The fund will trade ex-distribution on February 17, 2023. Only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan will have cash distributions automatically reinvested. Tekla Capital Management LLC, based in Boston, serves as the investment adviser for the fund.
On December 9, 2022, Tekla Healthcare Opportunities Fund (NYSE: THQ) announced a monthly cash distribution of $0.1125 per share. The record date for this distribution is December 19, 2022, with a payable date set for December 30, 2022. The Fund will trade ex-distribution on December 16, 2022. Only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan will automatically reinvest cash distributions in shares of the Fund.
Tekla Capital Management LLC, based in Boston, serves as the Fund's Investment Adviser.